// App-Quantinova.ai

2210 : Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study

Researchers

Presenter

  • Athimalaipet Ramanan

Principal Investigators

  • Pierre Quartier Dit Maire

  • Nami Okamoto

  • Gabriella Meszaros

  • Joana Araujo

  • Zhongkai Wang

  • Ran Liao

  • Brenda Crowe

  • Xin Zhang

  • Rodney Decker

  • Stuart Keller

  • Hermine Brunner

  • Nicola Ruperto

Medical Centers

  • Bristol Royal Hospital for Children, Bristol, United Kingdom

  • Necker hospital, Paris Cedex 15, France

  • Osaka Medical College, Takatsuki, Osaka, Japan

  • Eli Lilly and Company, Indianapolis, IN

  • Division of Rheumatology, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH

  • IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Genoa, Italy

Locations

  • United Kingdom

  • France

  • Japan

  • United States

  • Italy

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03773978

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved